About
Pepticom Ltd. develops an AI-driven platform that designs and discovers novel peptide therapeutics by exploring vast chemical spaces, leveraging reinforcement learning, structural data, and generative AI to optimize drug candidates for unmet medical needs, including their in-house oral IL-17 inhibitor program for plaque psoriasis.
Explore Pepticom Ltd.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.